# A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment

> **NCT05145270** · PHASE4 · UNKNOWN · sponsor: **Shanghai Mental Health Center** · enrollment: 180 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DIETARY_SUPPLEMENT:** Escitalopram+Sulforaphane
- **DEVICE:** Escitalopram+rTMS
- **DRUG:** Escitalopram

## Key facts

- **NCT ID:** NCT05145270
- **Lead sponsor:** Shanghai Mental Health Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-30
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2021-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05145270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05145270, "A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05145270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*